Pseudohypoaldosteronism type 2 (PHA2) is a rare inherited disorder characterized by persistent hyperkalemia and metabolic acidosis syndrome with normal or elevated serum aldosterone levels. This condition is due to dysfunction of sodium-magnesium-adenosine triphosphatase (Na+/K+-ATPase) in the renal tubules, which leads to impaired sodium and potassium reabsorption, resulting in hypoeclampsia, hypervolemia, and hypertension. Despite the presence of aldosterone in the blood, the symptoms of pseudohypoaldosteronism are due to the ineffectiveness of this hormone in the kidneys, which explains the pronounced clinical manifestations of this disease.
History of the disease and interesting historical facts
Pseudohypoaldosteronism was first described in the 1950s when researchers began studying fluid and electrolyte imbalances and their impact on blood pressure. The phenomenon attracted the attention of clinicians and scientists when cases of hyperkalemia with normal or elevated aldosterone levels began to be observed, challenging existing ideas about the role of this hormone in the body. One of the first landmark studies that led to an understanding of the mechanism of the disease was the observation of familial cases, indicating its hereditary nature. Since then, several types of pseudohypoaldosteronism have been identified, of which type 2, associated with mutations in the ENaC genes, has become the most studied.
Epidemiology
Pseudohypoaldosteronism type 2 is extremely rare, and its prevalence is not precisely established. The collected data suggest that the disease may occur with a frequency of 1 in 10,000 to 1 in 100,000 newborns. Examples of familial cases indicate that the disease is hereditary, although cases with new mutations are also sufficient. In some populations, such as people with African ancestry, the incidence may be higher due to an increased frequency of genetic mutations leading to this condition. Since the disease may remain undiagnosed for a long time, the real prevalence may be higher than officially registered cases.
Genetic predisposition to this disease
Pseudohypoaldosteronism type 2 is a genetically determined disease, related to autosomal recessive disorders. Most often, its development is caused by mutations in the genes encoding epithelial sodium channels (ENaC), which entail a violation of the function of sodium-potassium pumps in the renal tubules. In particular, mutations are known in the following genes:
- SCNN1A - alpha subunit of the epithelial sodium channel
- SCNN1B - beta subunit
- SCNN1G - gamma subunit
These mutations result in decreased Na+/K+-ATPase activity, which is responsible for the clinical manifestations of the disease. Some studies highlight the importance of genetic counseling for patients and their families, which allows for early detection of affected individuals.
Risk factors for the development of this disease
Although pseudohypoaldosteronism type 2 is primarily a genetic disorder, certain factors may contribute to its development:
- Hereditary predisposition. Since the disease is autosomal recessive, the presence of affected family members increases the risk of occurrence in offspring.
- Sexual factors. The disease does not have a pronounced sexual predisposition, but in women, symptoms may appear at different ages depending on hormonal changes.
- Environmental factors: Although there are no clearly defined exogenous or endogenous triggers for this disease, certain physiological conditions, such as pregnancy, may exacerbate the symptoms.
Other risk factors remain unclear and further research is needed to better understand these aspects.
Diagnosis of this disease
Diagnosis of pseudohypoaldosteronism type 2 requires a comprehensive approach and includes several key stages:
- Main symptoms: Major clinical manifestations include hyperkalemia, hypotension, metabolic acidosis, and signs of electrolyte disturbances.
- Laboratory tests: Determination of plasma potassium and sodium levels is a critical step. In the case of PGA2, high potassium levels and normal or elevated sodium levels are observed.
- Radiological examinations: An ultrasound of the kidneys can help identify structural changes, although it is not a specific diagnostic method.
- Other types of diagnostics: Genetic testing can confirm the presence of mutations in the relevant genes.
- Differential diagnosis: Other causes of hyperkalemia and metabolic acidosis, such as chronic kidney disease, hyperdonation, and other endocrine disorders, must be excluded.
Correct diagnosis requires a comprehensive approach that takes into account not only laboratory tests, but also clinical data.
Treatment
Treatment of pseudohypoaldosteronism type 2 is largely aimed at correcting the disturbances and monitoring electrolyte levels. Treatment tactics may include:
- General treatment: A low potassium diet and adequate hydration to correct hyperkalemia.
- Pharmacological treatment: Includes the use of diuretics to remove excess potassium, as well as drugs that promote increased sodium reabsorption.
- Surgical treatment: In rare cases, surgical correction of diseases that contribute to the development of the syndrome may be required.
- Other types of treatment: Support with an appropriate diet and, in some cases, the use of specialized aldosterone substitutes is important.
Since the condition is chronic, treatment must be long-term and individually tailored to the body's response to therapy.
List of medications used to treat this disease
- Spironolactone
- eplerenone
- Furosemide
- Torasemide
These drugs help control potassium levels and normalize electrolyte balance in the body. The choice of a specific drug depends on the clinical situation and the individual needs of the patient.
Disease monitoring
Monitoring of patients with pseudohypoaldosteronism type 2 includes regular checks of potassium and sodium levels, as well as clinical assessment of the patient. It is important to monitor blood pressure readings and signs of hypertension associated with the condition. The prognosis is generally good with prompt treatment and adherence to medical recommendations, although some patients may develop complications such as cardiac arrhythmias due to hyperkalemia. Regular communication with the treating physician and adherence to prescribed treatment regimens contribute to safer patient management.
Age-related features of the disease
The manifestations of pseudohypoaldosteronism type 2 may vary depending on the patient's age. In newborns and small children, symptoms may be more pronounced, which is associated with the insufficiency of compensatory mechanisms. In elderly patients, the disease may be less active, but existing concomitant pathologies may affect the course and manifestation of PGA2. It is important to consider age aspects when selecting treatment and monitoring the condition.
Questions and Answers
- What are the main symptoms of pseudohypoaldosteronism type 2? Major symptoms include hyperkalemia, metabolic acidosis and hypertension.
- How is pseudohypoaldosteronism type 2 diagnosed? Diagnosis includes laboratory tests, genetic testing and clinical examination of patients.
- What treatment is used for this disease? Treatment includes a low-potassium diet, medications to correct electrolyte imbalances, and monitoring.
- Is low aldosterone typical for this condition? No, aldosterone levels may be normal or elevated, but the action of this hormone is impaired.
- What is the prognosis for patients with pseudohypoaldosteronism type 2? The prognosis is usually favorable with proper treatment and adherence to doctor's recommendations.
